245 related articles for article (PubMed ID: 34125397)
1. Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Zarrin P; Dehghani Ashkezari M; Seifati SM
J Mol Neurosci; 2021 Dec; 71(12):2583-2592. PubMed ID: 34125397
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
3. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Jeon MY; Lee WY; Kang HY; Chung EJ
Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
6. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Zhang X; Andren PE; Chergui K; Svenningsson P
Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
[TBL] [Abstract][Full Text] [Related]
9. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Reksidler AB; Lima MM; Dombrowski PA; Barnabé GF; Andersen ML; Tufik S; Vital MA
J Neural Transm Suppl; 2009; (73):259-68. PubMed ID: 20411784
[TBL] [Abstract][Full Text] [Related]
11. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
12. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
14. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Datla KP; Blunt SB; Dexter DT
Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
[TBL] [Abstract][Full Text] [Related]
15. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
16. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
17. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Picconi B; Centonze D; Rossi S; Bernardi G; Calabresi P
Brain; 2004 Jul; 127(Pt 7):1661-9. PubMed ID: 15155524
[TBL] [Abstract][Full Text] [Related]
19. Levodopa Improves Behavioral Deficits of Mice with Parkinson's Disease Symptoms via Curbing NLRP3 Inflammasome Activation and Enhancing Tyrosine Hydroxylase Levels in the Striatum and Substantia Nigra.
Chen X; Wang Z; Yang W; Fu Y
J Integr Neurosci; 2024 Jan; 23(1):2. PubMed ID: 38287845
[TBL] [Abstract][Full Text] [Related]
20. Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.
Hu X; Yu L; Li Y; Li X; Zhao Y; Xiong L; Ai J; Chen Q; Wang X; Chen X; Ba Y; Wang Y; Wu X
CNS Neurosci Ther; 2024 Feb; 30(2):e14383. PubMed ID: 37528534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
